DANAVOREXTON
Danavorexton is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target orexin receptor type 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 2 | 1 | — | — | — | 3 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | 2 | 1 | — | — | — | 3 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | 2 | — | — | — | — | 2 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | 2 | — | — | — | — | 2 |
| Apnea | D001049 | — | R06.81 | 2 | — | — | — | — | 2 |
| Idiopathic hypersomnia | D020177 | — | G47.11 | 1 | — | — | — | — | 1 |
| Sleepiness | D000077260 | — | R40.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DANAVOREXTON |
| INN | danavorexton |
| Description | Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021.
|
| Classification | Small molecule |
| Drug class | Orexin receptor agonist |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@@H](c2ccccc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 2114324-48-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4650341 |
| ChEBI ID | — |
| PubChem CID | 130310079 |
| DrugBank | — |
| UNII ID | 1QMD83K4YN (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 61 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use